Rani Therapeutics

Rani Therapeutics was founded in 2012 by Mir Imran and develops smart capsules for oral drug delivery, which are usually injected. This capsule, called RaniPill, is coated with a gastric acid resistant layer. Once the capsule enters the small intestine, the coating dissolves, allowing the small balloon to inflate. Thanks to it, the drug is injected into the intestinal wall with a microneedle (which dissolves immediately after administration of the drug). The remaining part of the balloon "is excreted as a result of normal digestive processes."

History

2021: Exit to the exchange

In early August 2021, Rani Therapeutics, an American developer of smart capsules for oral drug administration, entered the exchange and raised $73 million thanks to this. In total, since its inception, the company has raised about $211.5 million.

Developer of smart capsules for oral administration of drugs Rani Therapeutics entered the exchange

Rani Therapeutics is developing capsules for drugs that have already been approved by regulators by early August 2021, but are not popular with patients due to the need for frequent regular injections. These drugs include octreotide used in acromegaly or neuroendocrine tumors of the gastrointestinal tract, TNF-alpha inhibitors for the treatment of psoriatic arthritis, parathyroid hormone (PTH) used in osteoporosis, somatotropic hormone for the treatment of STH deficiency, and parathyroid hormone for the treatment of hypothyroidism.

In the end, the company's goal is to prove that smart capsules can RaniPill be used in any cases, regardless of the drug administered. The company is seeking the right to test RaniPill in drug-free clinical trials to assess overall product safety. This study is planned to begin in 2022.^[1]

Notes